Taimed

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program

FOR IMMEDIATE RELEASE: February 9, 2012 Contact: Nelson Vergel (NelsonVergel@yahoo.com) Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program New York, February 9, 2012—AIDS activists and physician advocates welcome the news that ViiV Healthcare will be providing  expanded access of dolutegravir (DTG), a new investigational integrase inhibitor for HIV patients with …

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program Read More »

Pipeline Problems by David Evans In the past month, two companies shelved their once-promising experimental HIV drugs, citing the challenging nature of bringing a profitable product to market. Has the overwhelming success of modern-day HIV drugs jeopardized the future of new HIV treatment options? Since Matt Sharp first learned that he was HIV positive in …

Read More »

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options

Most successful HIV medication combinations require 3 medications that are fully active, but a small portion of long term survivors with long treatment history and accumulated HIV resistance mutations do not have the luxury of constructing a viable regimen to save their lives. Several potent antiretrovirals (ARVs) in the past 4 years have enabled many …

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options Read More »